IDEXX Laboratories is poised for growth in the pet healthcare market. Check out why I see a 50% upside in IDXX stock by FY27.

BofA analyst Michael Ryskin raised the firm’s price target on Idexx Laboratories (IDXX) to $535 from $475 and keeps a Neutral rating on the shares after the company reported a “strong” Q4 ...

IDEXX Laboratories, Inc. IDXX posted fourth-quarter 2024 earnings per share (EPS) of $2.62, up 12.9% year over year. The ...

Q4 2024 Earnings Call Transcript February 3, 2025 Operator: Good morning, and welcome to the IDEXX Laboratories’ Fourth ...

Idexx Laboratories posted higher-than-expected fourth-quarter revenue and provided its outlook for 2025. The veterinary technology-and-testing firm logged net income of $216.1 million, or $2.62 a ...

IDEXX Laboratories Inc (NASDAQ:IDXX) reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year, beating the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Net Margin: IDEXX Laboratories's net margin excels beyond industry benchmarks, reaching 23.87%. This signifies efficient cost management and strong financial health. Return on Equity (ROE): IDEXX ...

Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments. Idexx Laboratories offers a variety of products and diagnostic services ...

IDEXX Laboratories, Inc. ( NASDAQ: IDXX) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & ...

IDEXX Q4 adjusted EPS rose 10% YoY to $2.53 ... which offset inflationary cost impacts, favorable business mix benefits from strong consumable growth, and higher Water gross margins.